Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...
Revenue growth was fueled by oncology products, particularly ENHERTU, which retained leading market shares in the US, Europe ... Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC ... teeing it up as the first ADC for cervical cancer to hit Europe pending final authorization. As for biosimilars, CHMP ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
Europe as well as China, I visited all of their sites and I covered almost 90% of the employees in terms of market reach and explain with my own words the current state of Daiichi Sankyo and the ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective ...
Daiichi Sankyo’s board of directors followed the nomination committee’s report in making the appointment. Credit: ArDanMe/Shutterstock. Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback